Sustainable nanomedicine from olive leaf waste: biosynthesized ZnONPs with mechanistic validation against hepatocellular carcinoma.
7 affiliations
- 1Department of Pharmacognosy, Faculty of Pharmacy, Cairo University Kasr El Aini 11562 Cairo Egypt [email protected] [email protected] [email protected] [email protected].
- 2Department of Pharmacognosy, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport (AASTMT) Alexandria Egypt [email protected].
- 3Protein Research Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City) New Borg El-Arab City 21934 Alexandria Egypt [email protected] [email protected].
- 4Department of Phytochemistry and Plant Systematics, Pharmaceutical Division, National Research Centre Dokki 12622 Cairo Egypt [email protected].
- 5Department of Pharmacognosy, College of Pharmacy, King Khalid University Abha 62251 Saudi Arabia [email protected].
- 6Prince Faisal Bin Khalid Cardiac Centre - Aseer Cluster Abha 62521 Saudi Arabia [email protected].
- 7Department of Pharmacognosy and Natural Products, Faculty of Pharmacy, Pharos University in Alexandria Canal El Mahmoudia Street, Beside Green Plaza Complex 21648 Alexandria Egypt [email protected].
Abstract
Agri-food waste is an underutilized source of valuable bioactive compounds. In this study, olive leaf pruning residues (Olea europaea L. cv. Soury) were used for the green synthesis of zinc oxide nanoparticles (OL-ZnONPs) as a natural reducing and stabilizing agent. Physicochemical characterization showed that the OL-ZnONPs had a hexagonal wurtzite structure, a crystallite size of approximately 15.5 nm, 82.8% crystallinity, and a zeta potential of -23.7 mV. TEM and SEM-EDX analyses revealed aggregated spherical particles with sizes of 4.15 ± 1.23 nm and 0.192 ± 0.067 µm, respectively, with zinc and oxygen accounting for 75.29% and 24.71%, respectively. LC-ESI-MS/MS-MRM analysis identified and quantified 11 phenolic compounds, with rutin (354.15 µg g⁻¹), 3,4-dihydroxybenzoic acid (78.21 µg g⁻¹), and quercetin (45.75 µg g⁻¹) being the most abundant. OL-ZnONPs showed cytotoxic activity against HepG-2, MDA-MB-231, and HCT-116 cells, with the greatest selectivity toward HepG-2 cells (IC₅₀ = 0.344 µg mL⁻¹; SI = 5.279), compared with crude extract and 5-FU. OL-ZnONPs treatment increased intracellular levels of total caspase-3 and caspase-9, reduced TNF-α and IL-6 levels, induced nuclear changes consistent with apoptosis, and reduced HepG-2 cell migration. Network pharmacology was performed using the selected phenolic compounds together with ZnO to explore potential molecular mechanisms associated with the anti-hepatocellular carcinoma (HCC). A total of 801 anti-HCC-HepG-2 targets were predicted including AKT1, TP53, TNF, and IL6, CASP3 as hub genes in protein-protein interaction. The compound-target-pathway network identified quercetin, 3,4-dihydroxybenzoic acid, and ferulic acid as hub compounds. KEGG and GO enrichment analyses highlighted pathways in cancer, apoptosis, PI3K-Akt signaling, and chemical carcinogenesis-reactive oxygen species, providing exploratory mechanistic context for the experimental findings. Molecular docking predicted favorable binding of rutin and quercetin to AKT1. Collectively, these findings highlight the potential of OL-ZnONPs as an anticancer nanomaterial, particularly against HepG-2 cells, while supporting the valorization of olive leaf pruning residues aligns with the 2030 UN Sustainable Development Goal 3 (Good Health), SDG-9 (Industry/Innovation), SDG-12 (Responsible Consumption/Production), and SDG-13 (Climate Action). Further studies are required to clarify the contribution of the ZnO core and associated phytochemicals using size-matched bare ZnONPs, alongside in vivo evaluation of efficacy, biosafety, and pharmacokinetics.
Related
- Autonomous Nanomedicine: Closing the Biological Validation Gap
- A green and sustainable incorporation of bi- and ter-thiophenes into 1,4-dihydropyridines: synthetic, mechanistic and photophysical investigations
- Mechanistic Insights Into Sustainable Catalytic Pyrolysis of Biomass‐Derived Ferulic Acid: The Role of Alumina Regeneration
- Metal–Organic Framework (MOF)-Based Catalytic Systems for Multicomponent Reactions in Sustainable Heterocycle Synthesis: Recent Advances, Mechanistic Insights, and Future Perspectives
- Characterization and Antibacterial Activity of Biosynthesized Zinc Oxide–Silver (ZnO–Ag) Nanocomposites Using Manihot esculenta Leaf Extract
BibTeX
@article{mohamaden2026sustainable,
title = {{Sustainable nanomedicine from olive leaf waste: biosynthesized ZnONPs with mechanistic validation against hepatocellular carcinoma.}},
author = {Yasmin Mounir Mohamaden and Seham S El-Hawary and Esmail M El-Fakharany and Yousra A El-Maradny and Mohamed El Raey and Amira Safwat El Senousy and Mohamed A Rabeh and Mohammad D Al-Zaid and Samar M Bassam},
journal = {RSC advances},
year = {2026},
month = oct,
doi = {10.1039/d6ra01605g},
url = {https://europepmc.org/article/MED/42840978},
note = {CC BY},
}
RIS
TY - JOUR
TI - Sustainable nanomedicine from olive leaf waste: biosynthesized ZnONPs with mechanistic validation against hepatocellular carcinoma.
AU - Yasmin Mounir Mohamaden
AU - Seham S El-Hawary
AU - Esmail M El-Fakharany
AU - Yousra A El-Maradny
AU - Mohamed El Raey
AU - Amira Safwat El Senousy
AU - Mohamed A Rabeh
AU - Mohammad D Al-Zaid
AU - Samar M Bassam
PY - 2026
DA - 2026/10/06
JO - RSC advances
DO - 10.1039/d6ra01605g
UR - https://europepmc.org/article/MED/42840978
AB - Agri-food waste is an underutilized source of valuable bioactive compounds. In this study, olive leaf pruning residues (Olea europaea L. cv. Soury) were used for the green synthesis of zinc oxide nanoparticles (OL-ZnONPs) as a natural reducing and stabilizing agent. Physicochemical characterization showed that the OL-ZnONPs had a hexagonal wurtzite structure, a crystallite size of approximately 15.5 nm, 82.8% crystallinity, and a zeta potential of -23.7 mV. TEM and SEM-EDX analyses revealed aggregated spherical particles with sizes of 4.15 ± 1.23 nm and 0.192 ± 0.067 µm, respectively, with zinc and oxygen accounting for 75.29% and 24.71%, respectively. LC-ESI-MS/MS-MRM analysis identified and quantified 11 phenolic compounds, with rutin (354.15 µg g⁻¹), 3,4-dihydroxybenzoic acid (78.21 µg g⁻¹), and quercetin (45.75 µg g⁻¹) being the most abundant. OL-ZnONPs showed cytotoxic activity against HepG-2, MDA-MB-231, and HCT-116 cells, with the greatest selectivity toward HepG-2 cells (IC₅₀ = 0.344 µg mL⁻¹; SI = 5.279), compared with crude extract and 5-FU. OL-ZnONPs treatment increased intracellular levels of total caspase-3 and caspase-9, reduced TNF-α and IL-6 levels, induced nuclear changes consistent with apoptosis, and reduced HepG-2 cell migration. Network pharmacology was performed using the selected phenolic compounds together with ZnO to explore potential molecular mechanisms associated with the anti-hepatocellular carcinoma (HCC). A total of 801 anti-HCC-HepG-2 targets were predicted including AKT1, TP53, TNF, and IL6, CASP3 as hub genes in protein-protein interaction. The compound-target-pathway network identified quercetin, 3,4-dihydroxybenzoic acid, and ferulic acid as hub compounds. KEGG and GO enrichment analyses highlighted pathways in cancer, apoptosis, PI3K-Akt signaling, and chemical carcinogenesis-reactive oxygen species, providing exploratory mechanistic context for the experimental findings. Molecular docking predicted favorable binding of rutin and quercetin to AKT1. Collectively, these findings highlight the potential of OL-ZnONPs as an anticancer nanomaterial, particularly against HepG-2 cells, while supporting the valorization of olive leaf pruning residues aligns with the 2030 UN Sustainable Development Goal 3 (Good Health), SDG-9 (Industry/Innovation), SDG-12 (Responsible Consumption/Production), and SDG-13 (Climate Action). Further studies are required to clarify the contribution of the ZnO core and associated phytochemicals using size-matched bare ZnONPs, alongside in vivo evaluation of efficacy, biosafety, and pharmacokinetics.
SN - 2046-2069
ER -